On Tuesday, SHFL Entertainment (NASDAQ: SHFL ) will release its latest quarterly results. The company formerly known as Shuffle Master faces a huge opportunity in the rapidly evolving gaming market, but it will have to work hard to cash in.
SHFL Entertainment makes a variety of products that casinos use, ranging from its namesake Shuffle Master card-shuffling devices, to tracking devices designed to analyze table-game play and detect potential fraud. As the industry moves toward more electronic gaming, however, the company has also seen success in its electronic table systems and other related machines. Let's take an early look at what's been happening with SHFL Entertainment over the past quarter, and what we're likely to see in its quarterly report.
Stats on SHFL Entertainment
Analyst EPS Estimate
$0.20
Change From Year-Ago EPS
KeyCorp is a bank holding company for KeyBank National Association (KeyBank). Through KeyBank and certain other subsidiaries, the Company provides a range of retail and commercial banking, commercial leasing, investment management, consumer finance and investment banking products and services to individual, corporate and institutional clients through two business segments: Key Community Bank and Key Corporate Bank. As of December 31, 2011, these services were provided through KeyBank�� 1,058 full-service retail banking branches in 14 states, additional offices, a telephone banking call center services group and a network of 1,579 automated teller machines (ATMs) in 15 states. On January 17, 2012, the Company opened another national bank subsidiary.
In addition to the banking services of accepting deposits and making loans, the Bank and trust company subsidiaries offer personal and corporate trust services, personal financial services, access to mutual funds, cash management services, investment banking and capital markets products, and international banking services. Through its bank, trust company and investment adviser subsidiaries, the Company provides investment management services to clients that include corporate and public retirement plans, foundations and endowments, individuals and trust funds. The Company provides other financial services - both within and outside of its primary banking markets - through various nonbank subsidiaries. These services include community development financing, securities underwriting and brokerage. It is also an equity participant in a joint venture that provides merchant services to businesses.
Lending Activities
As of December 31, 2011, the Company�� Commercial, Financial and Agricultural loans, also referred to as Commercial and Industrial, represented 39% of its total loan portfolio. As of December 31, 2011, commercial real estate loans represented approximately 19% of its total loan portfolio. These loans include bo! th owner and nonowner-occupied properties and constitute approximately 27% of its commercial loan portfolio. Its commercial real estate lending business is conducted through two primary sources: its 14-state banking franchise, and Real Estate Capital and Corporate Banking Services. The Company conducts financing arrangements through its equipment finance line of business. Commercial lease financing receivables represented 17% of commercial loans at December 31, 2011. The home equity portfolio is the largest segment of its consumer loan portfolio.
Investment Activities
The Company�� securities portfolio totaled $18 billion at December 31, 2011. Available-for-sale securities were $16 billion at December 31, 2011. Held-to-maturity securities were $2.1 billion at December 31, 2011. At December 31, 2011, it had $2.1 billion in collateralized mortgage obligations (CMOs) in its held-to-maturity securities portfolio. At December 31, 2011, the Company had $15.9 billion invested in CMOs and other mortgage-backed securities in the available-for-sale portfolio. Federal Agency CMOs constitute most of its held-to-maturity securities along with foreign bonds and preferred equity securities. The investments in equity and mezzanine instruments made by its principal investing unit represented 61% of other investments at December 31, 2011. They include direct investments (investments made in a particular company), as well as indirect investments (investments made through funds that include other investors).
Sources of Funds
Domestic deposits are the Company�� primary source of funding. During the year ended December 31, 2011, these deposits averaged $58.5 billion and represented 80% of the funds it used to support loans and other earning assets. Wholesale funds, consisting of deposits in its foreign office and short-term borrowings, averaged $3.4 billion during 2011. At December 31, 2011, the Company had $4.7 billion in time deposits of $100,000 or more.
Advisors' Opinion: - [By Matt Egan]
He will be replaced by Hancock, 55, who joined the company from KeyCorp (KEY) in 2010 and became CEO of AIG Property Casualty in March 2011. He also worked at JPMorgan Chase (JPM) for two decades, establishing the bank's global derivatives group and running its global fixed income business.
Top 10 Healthcare Equipment Companies To Buy Right Now: bluebird bio Inc (BLUE)
bluebird bio, Inc., incorporated on April 16, 1992, is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient�� own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient�� cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. As of December 31, 2012, the Company is conducting a Phase I/II clinical study in France evaluating an earlier generation of its LentiGlobin vector for the treatment of �-thalassemia major and SCD. Initial proof-of-concept data from this study were published in Nature. During the year ended December 31, 2013, the Company plans to initiate an extension of this study under a revised protocol for LentiGlobin, which the Company refers to as the HGB-205 Study. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for �-thalassemia major. In March 2013, the Company entered into a strategic collaboration with Celgene Corporation, or Celgene, to discover, develop and commercialize, disease-altering gene therapies in oncology.
Its gene therapy platform is based on viral vectors that utilize a modified, non-replicating version of the Human Immunodeficiency Virus Type 1 (HIV-1) virus, that has been stripped of all of the components required for it to self-replicate and infect additional cells. The HIV-1 virus is part of the lentivirus family of viruses, as a result of which the Company refer to its vectors as lentiviral vectors. Its lentiviral vectors are used to introduce a functional copy of a gene to the patient�� own isolated blood stem cells, called hematopoietic stem cells (HSCs), which reside in a patient�� bone marrow and are capable of differentiating int! o a wide range of cell types. HSCs are dividing cells, thus its approach allows for sustained expression of the modified gene as the Company is able to take advantage of a lifetime of replication of the gene-modified HSCs. Additionally, the Company has developed a cell-based vector manufacturing process that is both reproducible and scalable.
Adrenoleukodystrophy
Adrenoleukodystrophy is a rare X-linked, inherited, neurological disorder that is often fatal. ALD is caused by mutations in the ABCD1 gene which encodes for a protein called the ALD protein (ALDP), which plays a critical role in the breakdown and metabolism of long-chain fatty acids (VLCFA). Without functional ALDP, VLCFA accumulate in cells including neural cells in which they cause damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. ALD is divided into various sub-segments with three main phenotypes that impact brain function: CCALD (Childhood cerebral adrenoleukodystrophy, AMN (Adrenomyeloneuropathy) and ACALD (Adult Cerebral ALD).
�-thalassemia
�-thalassemia is a rare hereditary blood disorder caused by a genetic abnormality of the �-globin gene resulting in defective red blood cells (RBCs). Genetic mutations cause the absence or reduced production of the beta chains of hemoglobin, or �-globin, thereby preventing the proper formation of hemoglobin A, which normally accounts for greater than 95% of the hemoglobin in the blood of adults. Hemoglobin is an iron-containing protein in the blood that carries oxygen from the respiratory organs to the rest of the body. Hemoglobin A consists of four chains-two chains each of a-globin and �-globin. Normally existing at an approximate 1:1 ratio, genetic mutations that impair t! he produc! tion of �-globin can lead to a relative excess of a-globin, premature death of red blood cells. The clinical implications of the a-globin/�-globin imbalance are two-fold: first, patients lack sufficient RBCs and hemoglobin to effectively transport oxygen throughout the body and can become severely anemic; and second, the shortened life span and ineffective production of RBCs can lead to other complications such as splenomegaly, marrow expansion, bone deformities, and iron overload in organs.
Sickle cell disease
Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the �-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The disease is characterized by anemia, vaso-occlusive pain crisis (a common complication of SCD in which there is severe pain due to obstructed blood flow in the bones, joints, lungs, liver, spleen, kidney, eye, or central nervous system), infections, stroke, overall poor life and early death in a subset of patients. Under low-oxygen conditions, which are exacerbated by the red blood cell abnormalities, the mutant hemoglobin aggregates causing the RBCs to take on a sickle shape (sickle cells), which causes them to aggregate and obstruct small blood vessels, thereby restricting blood flow to organs resulting in pain, cell death and organ damage. If oxygen levels are restored, the hemoglobin can disaggregate and the RBCs return to their normal shape, but over time, the sickling damages the cell membrane and the cells fail to return to the normal shape even in high-oxygen conditions.
Advisors' Opinion: - [By David Williamson]
In this video, health-care analyst David Williamson takes a look at the tremendous success of the�Bluebird Bio (NASDAQ: BLUE ) �IPO. The company increased the size of its initial public offering, and priced shares at $17 -- above the top end of its range -- but that still couldn't contain investor appetite for this stock. Shares shot up 50% on the opening day of trading, and have remained there.
Top 10 Healthcare Equipment Companies To Buy Right Now: ING Groep NV (INGA)
ING Groep N.V. (ING) is a global financial institution offering banking, investments, life insurance and retirement services to meet the needs of the customers. The Company�� segments include banking and insurance. Banking segment includes retail Netherlands, retail Belgium, ING direct, retail central Europe (CE), retail Asia, commercial banking (excluding real estate), ING real estate and corporate line banking. Insurance segment includes insurance Benelux, insurance central and rest of Europe (CRE), insurance United States (US), Insurance US closed block VA, insurance Asia/Pacific, ING investment management (IM) and corporate line insurance. In November 2013, the Company completed the sale of ING Hipotecaria to Banco Santander (Mexico), S.A. In December 2013, the Company completed the sale of its 33.3% interest in China Merchants Fund to its joint venture partners China Merchants Bank Co Ltd and China Merchants Securities Co Ltd, and divested ING Life Korea to MBK Partners.
Advisors' Opinion: - [By Sofia Horta e Costa]
ING (INGA), which received a 10 billion-euro government bailout in 2008, gained 5.1 percent to 8.26 euros. Underlying pretax profit for the banking unit rose 14 percent to 1.15 billion euros in the second quarter as the interest margin improved and cost cuts paid off, the biggest Dutch financial-services company said.
Top 10 Healthcare Equipment Companies To Buy Right Now: TriQuint Semiconductor Inc.(TQNT)
TriQuint Semiconductor, Inc. provides radio frequency (RF) solutions and technology for communications, defense, and aerospace companies worldwide. The company designs, develops, and manufactures RF solutions with gallium arsenide (GaAs), gallium nitride, bipolar high electron mobility transistor, surface acoustic wave (SAW), temperature compensated surface acoustic wave, bulk acoustic wave (BAW), copper flip, and wafer level packaging technologies. The company offers an array of filtering, switching, and amplification products for RF, microwave, and millimeter-wave applications. It sells electronic components for mobile phones, including transmit modules, RF filters, power amplifiers and power amplifier modules, duplexers, switches, other RF devices, and integrated products to mobile device manufacturers. The company also offers signal amplification and filtering products, including a portfolio of GaAs microwave monolithic integrated circuits and transistors, and SAW and BAW filter components that support the transfer of voice, data, and video across wireless or wired infrastructure. Its network products comprise millimeter wave power amplifiers, frequency converters, and voltage controlled oscillators. In addition, the company provides defense and aerospace devices, including packaged products, die-level integrated circuits (ICs), microwave monolithic ICs, and multi-chip modules to military contractors serving the U.S. government for use in various communications and phased array radar programs, such as ship-based, airborne, and battlefield systems, as well as sat-com, electronic warfare, and guidance applications. Further, TriQuint Semiconductor, Inc. offers foundry services. The company sells its products through independent manufacturers? representatives, independent distributors, and direct sales staff. TriQuint Semiconductor, Inc. was founded in 1981 and is headquartered in Hillsboro, Oregon.
Advisors' Opinion: - [By Timothy Green]
Key points
RF Micro is set to merge with TriQuint Semiconductor (NASDAQ: TQNT ) by the end of this year, and during the second quarter shareholders of both companies officially approved the combination. The merger will give the combined company greater scale, with the hopes of improving both profitability and competitiveness.
Top 10 Healthcare Equipment Companies To Buy Right Now: Extra Space Storage Inc (EXR)
Extra Space Storage, Inc. operates as a real estate investment trust (REIT) in the United States. It engages in property management and development activities that include acquiring, managing, developing, and selling, as well as the rental of self-storage facilities. As of December 31, 2006, Extra Space Storage owned interests in 567 properties located in 32 states and Washington, D.C., as well as managed 74 properties owned by franchisees or third parties. As a REIT, the company would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1977 and is based in Salt Lake City, Utah.
Advisors' Opinion: - [By Rich Duprey]
Real estate investment trust�Extra Space Storage (NYSE: EXR ) announced yesterday its third-quarter dividend of $0.40 per share, the same rate it paid last quarter after raising the payout 60%, from $0.25 per share.
Top 10 Healthcare Equipment Companies To Buy Right Now: Ethan Allen Interiors Inc (ETH)
Ethan Allen Interiors Inc. (Ethan Allen), incorporated in May 25, 1989, through its wholly owned subsidiary, Ethan Allen Global, Inc. and Ethan Allen Global, Inc.�� subsidiaries, is a manufacturer and retailer of home furnishings and accessories, offering a complement of home decorating and design solutions through home furnishing retail networks. The Company operates in two segments: wholesale and retail. As of June 30, 2013, the Company operated 147 design centers and its independent retailers operated 148 design centers. Its wholesale segment net sales include sales to its retail segment and sales to its independent retailers. During the fiscal year ended June 30, 2013 (fiscal 2013), independent retailers opened 11 new design centers, acquired two from the Company, closed 12, and sold two to the Company.
The Company�� customer service offerings include gift card, on-line room planning and Ethan Allen Consumer Credit Programs. Gift Card allows customers to purchase gift cards through its Website or at any participating retail design center, which can be redeemed for any of its products or services. The Company offers, through its Website, an online room planning resource, which serves to assist consumers with their home decorating needs. Through the use of this Web-based tool, customers can determine which of its product offerings fit their particular needs based on their own individual home floor plan. The Ethan Allen Finance Plus program offers consumers (clients) a menu of custom financing options through the use of just one account.
Wholesale Segment
The wholesale segment, principally involved in the development of the Ethan Allen brand, encompasses all aspects of design, manufacture, sourcing, sale, and distribution of its range of home furnishings and accessories. Wholesale revenue is generated upon the wholesale sale and shipment of its products to its network of independently operated design centers and Company-operated design centers through its na! tional distribution center and one other smaller fulfillment center. The Company�� domestic manufacturing is included in the results of the wholesale segment. The Company operates four case plants (including one sawmill), three upholstery plants (two upholstery plants on its Maiden, North Carolina campus and one cut and sew plant in Mexico) and one home accessory plant. The Company also source selected case goods, upholstery, and home accessory items from third-party suppliers located both domestically and outside the United States.
Retail Segment
The retail segment sells home furnishings and accessories to consumers through a network of Company-operated design centers. During fiscal 2013, the Company opened seven design centers acquired two from independent retailers, closed four design centers and sold two to our independent retailers. As of June 30, 2013, the Company�� network of approximately 300 retail design centers and approximately 4,000 independent members of the Interior Design Affiliate program benefit from these marketing efforts.
Advisors' Opinion: - [By Dividends4Life]
Memberships and Peers: LEG is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers��Index and a Dividend Champion. The company's peer group includes: Hooker Furniture Corp. (HOFT) with a 2.4% yield, Flexsteel Industries Inc. (FLXS) with a 2.7% yield and Ethan Allen Interiors Inc. (ETH) with a 1.4% yield.
- [By Ben Levisohn]
As if to drive that point home, the Gap (GPS) is getting hammered–its shares have dropped 6.6% to $36.89 today– after its same store sales fell 3%, below analyst forecasts for a gain of 1.6%. Ethan Allen (ETH), meanwhile, has fallen 4.3% to $26.32 after the retailer said earnings would come in between 30 cents and 32 cents, below forecasts for 40 cents.
Top 10 Healthcare Equipment Companies To Buy Right Now: Brainstorm Cell Therapuetics Inc (BCLI)
Brainstorm Cell Therapeutics Inc. (Brainstorm), incorporated on November 15, 2006, is a biotechnology company developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson�� disease (PD). These diseases have limited treatment options and as such represent unmet medical needs. The Company�� NurOwn technology is based on a differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells, MSC-NTF cells, capable of releasing several neurotrophic factors, including Glial-derived neurotrophic factor (GDNF) and Brain-derived neurotrophic factor (BDNF), Vascular endothelial growth factor (VEGF) and Hepatocyte growth factor (HGF), which are critical for the growth, survival and differentiation of developing neurons.
The Company�� approach to treatment of neurodegenerative diseases with autologous adult stem cells includes a multi-step process beginning with harvesting of undifferentiated stem cells from the patient's own bone marrow, and concluding with transplantation of differentiated, neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) into the same patient-intrathecally and/or intramuscularly. Intrathecal (injection into the cerebrospinal fluid) transplantation consists of injection with a standard lumbar puncture; there is no need for a laminectomy -an invasive, orthopedic spine operation to remove a portion of the vertebral bone, as required by other technologies. Intramuscular (injection directly into muscle) transplantation is performed via a standard injection procedure as well. Its production process for induction of differentiation of human bone marrow derived mesenchymal stem cells into differentiated cells that produce NTF (MSC-NTF) for clinical use is conducted in full compliance with current Good Manufacturing Practice (cGMP).
Advisors' Opinion: - [By John Udovich]
Small cap ALS and stem cell stock�Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) surged 22.68%�ahead if its Monday ice bucket challenge when they will release the final results from�a phase 2a clinical trial���meaning its worth taking a closer look at the stock along with the performance of stem cell stocks or ALS stocks like Cytokinetics, Inc (NASDAQ: CYTK), Neuralstem, Inc (NYSEMKT: CUR) and NeoStem Inc (NASDAQ: NBS). However, Brainstorm Cell Therapeutics does have a history of being the subject of paid promotions and/or investor relations activities when it was trading on the OTC.